These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3950056)

  • 1. Pharmacokinetics of cibenzoline after single and repetitive dosing in healthy volunteers.
    Massarella JW; Khoo KC; Szuna AJ; Sandor DA; Morganroth J; Aogaichi K
    J Clin Pharmacol; 1986 Feb; 26(2):125-30. PubMed ID: 3950056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose pharmacokinetics and dose proportionality of oral cibenzoline.
    Khoo KC; Szuna AJ; Colburn WA; Aogaichi K; Morganroth J; Brazzell RK
    J Clin Pharmacol; 1984 Jul; 24(7):283-8. PubMed ID: 6480874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age and cibenzoline disposition.
    Brazzell RK; Rees MM; Khoo KC; Szuna AJ; Sandor D; Hannigan J
    Clin Pharmacol Ther; 1984 Nov; 36(5):613-9. PubMed ID: 6488682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cibenzoline in patients with renal impairment.
    Canal M; Flouvat B; Aubert P; Guedon J; Prinseau J; Baglin A
    J Clin Pharmacol; 1985 Apr; 25(3):197-203. PubMed ID: 3998200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function.
    Aronoff G; Brier M; Mayer ML; Barbalas M; Aogaichi K; Sloan R; Brazzell R; Massarella J
    J Clin Pharmacol; 1991 Jan; 31(1):38-44. PubMed ID: 2045527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of renal impairment on the pharmacokinetics of cibenzoline.
    Massarella JW; Khoo KC; Aogaichi K; Di Persio D; Smith M; Kluger J; Chow MS
    Clin Pharmacol Ther; 1988 Mar; 43(3):317-23. PubMed ID: 3345622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral cibenzoline on steady-state digoxin concentrations in healthy volunteers.
    Khoo KC; Givens SV; Parsonnet M; Massarella JW
    J Clin Pharmacol; 1988 Jan; 28(1):29-35. PubMed ID: 3350991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of intravenous cibenzoline in normal volunteers.
    Brazzell RK; Khoo KC; Szuna AJ; Sandor D; Aogaichi K; Wills RJ
    J Clin Pharmacol; 1985 Sep; 25(6):418-23. PubMed ID: 4056077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of congestive heart failure on the pharmacokinetics of cibenzoline.
    Massarella JW; Silvestri T; DeGrazia F; Miwa B; Keefe D
    J Clin Pharmacol; 1987 Mar; 27(3):187-92. PubMed ID: 3680572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics in man of a new antiarrhythmic drug, cibenzoline.
    Canal M; Flouvat B; Tremblay D; Dufour A
    Eur J Clin Pharmacol; 1983; 24(4):509-15. PubMed ID: 6861865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The disposition and metabolic fate of 14C-cibenzoline in man.
    Massarella JW; Loh AC; Williams TH; Szuna AJ; Sandor D; Bressler R; Leinweber FJ
    Drug Metab Dispos; 1986; 14(1):59-64. PubMed ID: 2868867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of time of dosing on the disposition of oral cibenzoline.
    Brazzell RK; Khoo KC; Schneck DW
    Biopharm Drug Dispos; 1985; 6(4):433-40. PubMed ID: 4084668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
    Bramer SL; Forbes WP; Mallikaarjun S
    Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of oral cibenzoline in arrhythmia patients.
    Brazzell RK; Colburn WA; Aogaichi K; Szuna AJ; Somberg JC; Carliner N; Heger J; Morganroth J; Winkle RA; Block P
    Clin Pharmacokinet; 1985; 10(2):178-86. PubMed ID: 3995859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of food on cibenzoline bioavailability.
    Massarella JW; Blumenthal HP; Silvestri T; Lin A
    Eur J Clin Pharmacol; 1986; 30(3):367-9. PubMed ID: 3732378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study.
    Zhou H; Wu G; Hu X; Zhu M; Zhai Y; Liu J; Shentu J; Wu L
    Clin Ther; 2015 Jun; 37(6):1292-300. PubMed ID: 25869627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart failure elevates serum levels of cibenzoline in arrhythmic patients.
    Kotake T; Takada M; Komamura K; Kamakura S; Miyatake K; Kitakaze M; Morishita H
    Circ J; 2006 May; 70(5):588-92. PubMed ID: 16636495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses.
    Moore SA; Muñana KR; Papich MG; Nettifee-Osborne J
    Am J Vet Res; 2010 Mar; 71(3):337-41. PubMed ID: 20187836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.